Tag: Synthetic GnRH antagonist

  • Cetrorelix

    Synthetic GnRH antagonist

    A synthetic GnRH receptor antagonist used in IVF protocols to prevent premature LH surge; immediate suppression without the agonist flare.

    Abstract

    Cetrorelix (Ac-D-2-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; CAS 120287-85-6; molecular formula C70H92ClN17O14; molecular weight 1431.06) is a synthetic GnRH receptor antagonist decapeptide developed at ASTA Medica and approved by the FDA in 2000 under the trade name Cetrotide. Mechanism: competitive antagonism at pituitary GnRH receptors, producing immediate dose-dependent suppression of LH and FSH without the initial flare characteristic of GnRH agonists. The antagonist mechanism allows brief, on-demand HPG suppression without the 7-to-10-day desensitization period required for GnRH agonist effect. Plasma half-life is approximately 60 hours after subcutaneous dosing. Approved for prevention of premature LH surge in controlled ovarian stimulation for IVF; the daily dose protocol begins on stimulation day 5 and continues through hCG trigger. Off-label use in benign prostatic hyperplasia and prostate cancer (where the avoidance of testosterone flare is clinically valuable). Used as the canonical GnRH antagonist in IVF research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Ganirelix

    Synthetic GnRH antagonist

    A synthetic GnRH receptor antagonist; mechanistically similar to cetrorelix and used in the same IVF protocols.

    Abstract

    Ganirelix (Ac-D-2-Nal-D-Cpa-D-Pal-Ser-Tyr-D-(Et)2HArg-Leu-(Et)2HArg-Pro-D-Ala-NH2; CAS 124904-93-4; molecular formula C80H113ClN18O13; molecular weight 1570.35) is a synthetic GnRH antagonist decapeptide developed at Organon and approved by the FDA in 1999 under the trade name Antagon (US) and Orgalutran (EU). Mechanism is identical to cetrorelix: competitive GnRH receptor antagonism producing immediate dose-dependent LH and FSH suppression. Structurally distinct from cetrorelix by the diethylhomoarginine residues at positions 6 and 8. Plasma half-life is approximately 13 hours after subcutaneous dosing, shorter than cetrorelix but adequate for daily IVF protocol dosing. Approved for prevention of premature LH surge in controlled ovarian stimulation for IVF. Comparable clinical efficacy to cetrorelix in head-to-head trials. Used as an alternative GnRH antagonist in IVF and HPG suppression research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.